Professor Daniel Brodie, the President of the International Extracorporeal Organization (ELSO) and Director of Critical Care from New-York Columbia - Presbyterian Hospital, Has Joined Inspira Technologies' Advisory Board

Professor Daniel Brodie,

the President of the International Extracorporeal Organization (ELSO) and Director of Critical Care from New-York Columbia - Presbyterian

Hospital, Has Joined Inspira Technologies' Advisory Board

Israel, January 19, 2022 - Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira

Technologies"), a groundbreaking respiratory support technology company, announced today that Professor Daniel Brodie, an expert

in critical care medicine and extracorporeal life support methods, has joined Inspira Technologies' Scientific Advisory Board.

Brodie's appointment to the Scientific Advisory Board follows the appointments of Prof. Eddy Fan and Dr. Stephan Ledot, world-renowned

key opinion leaders in intensive care medicine and extracorporeal life support.

Brodie is the Section Chief for Critical Care within the Division of Pulmonary, Allergy and Critical Care Medicine, the Director of the

Adult ECMO Program and the Director of the Center for Acute Respiratory Failure at the Columbia University/New York-Presbyterian Hospital.

is the President-elect of the Extracorporeal Life Support Organization (ELSO) and the chairman of the Executive Committee of the International

ECMO Network (ECMONet) - two leading international organizations spearheading scientific knowledge in the field of extracorporeal

life support. He is currently on the steering committee of numerous ongoing and upcoming clinical trials in the field. In addition, Prof.

Brodie serves as a member of the National Heart, Lung, and Blood Institute's (NHLBI) Protocol Review Committee for the Prevention

and Early Treatment of Acute Lung Injury (PETAL) Network.

has served as a reviewer in influential scientific journals, including New England Journal of Medicine, The Lancet and The Journal

of American Medical Association (JAMA). Prof Brodie has authored more than 300 peer-reviewed publications and book chapters and has

delivered nearly 400 invited lectures throughout the world.

Ben-Noon, Chief Executive Officer of Inspira Technologies, stated: "It is a great honor to have Professor Brodie on Inspira Technologies'

Scientific Advisory Board. Professor Brodie is a distinguished physician, researcher, and lecturer whose scientific and clinical work

About Inspira Technologies OXY B.H.N. Ltd.

Technologies is an innovative medical device company in the respiratory care industry. Inspira is developing the ART device, a cost effective

early extracorporeal respiratory support system with an intent to function as an "Artificial Lung" for deteriorating respiratory

patients. The ART device is designed to utilize a hemo-protective flow approach aimed at rebalancing oxygen saturation levels while patients

are awake and breathing, potentially minimizing the patient's need for mechanical ventilation. The Company's product has not yet

been tested or used in humans and has not been approved by the U.S. Food and Drug Administration (FDA) or the CE or other required regulatory

more information, please visit our corporate website: www.inspirao2.com

Statement Disclaimer

press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements

and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors

and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except

as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements

to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information

about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's

Registration Statement on Form F-1 filed with the SEC, as well as its subsequent public filings, which are available on the SEC's

website, www.sec.gov.

Miri Segal, Investor

Relations, MS-IR LLC, +917-607-8654, msegal@ms-ir.com